Evading the Immune System: Immune Modulation and Immune Matching in Cell Replacement Therapies for Parkinson's Disease

Overview

Journal J Parkinsons Dis

Publisher Sage Publications

Specialty Neurology

Date 2021 May 24

PMID 34024783

Citations 3

Authors

Asuka Morizane

Jun Takahashi

Affiliations

Soon will be listed here.

Abstract

Stem cell-based therapies for Parkinson's disease are now being applied clinically. Notably, studies have shown that controlling the graft-induced immune response improves the results. In this mini-review, we concisely summarize current approaches used for this control. We focus on four modes of stem cell-based therapies: autologous transplantation, allogeneic transplantation with human leukocyte antigen-matching and allogeneic transplantation without, and finally the application of "universal" pluripotent stem cells. We also discuss immuno-suppressive treatments and the monitoring of immune reactions in the brain.

Citing Articles

Challenges involved in cell therapy for Parkinson's disease using human pluripotent stem cells.

Moon H, Kim B, Kwon I, Oh Y Front Cell Dev Biol. 2023; 11:1288168.

PMID: 37886394 PMC: 10598731. DOI: 10.3389/fcell.2023.1288168.

Advancements in Autologous Stem Cell Transplantation for Parkinson's Disease.

Shi J, Zhang K Curr Stem Cell Res Ther. 2023; 19(10):1321-1327.

PMID: 37691194 DOI: 10.2174/1574888X19666230907112413.

Long-Term Evaluation of Intranigral Transplantation of Human iPSC-Derived Dopamine Neurons in a Parkinson's Disease Mouse Model.

Brot S, Thamrin N, Bonnet M, Francheteau M, Patrigeon M, Belnoue L Cells. 2022; 11(10).

PMID: 35626637 PMC: 9140181. DOI: 10.3390/cells11101596.

References

Wickstrom T, Clarke A, Gausemel I, Horn E, Jorgensen K, Khan I . The development of an automated and GMP compliant FASTlab™ Synthesis of [(18) F]GE-180; a radiotracer for imaging translocator protein (TSPO). J Labelled Comp Radiopharm. 2014; 57(1):42-8. DOI: 10.1002/jlcr.3112. View

Sugita S, Iwasaki Y, Makabe K, Kamao H, Mandai M, Shiina T . Successful Transplantation of Retinal Pigment Epithelial Cells from MHC Homozygote iPSCs in MHC-Matched Models. Stem Cell Reports. 2016; 7(4):635-648. PMC: 5063629. DOI: 10.1016/j.stemcr.2016.08.010. View

Morizane A, Doi D, Kikuchi T, Okita K, Hotta A, Kawasaki T . Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Reports. 2013; 1(4):283-92. PMC: 3849265. DOI: 10.1016/j.stemcr.2013.08.007. View

Doi D, Magotani H, Kikuchi T, Ikeda M, Hiramatsu S, Yoshida K . Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease. Nat Commun. 2020; 11(1):3369. PMC: 7338530. DOI: 10.1038/s41467-020-17165-w. View

Elmer B, Kimberley McAllister A . Major histocompatibility complex class I proteins in brain development and plasticity. Trends Neurosci. 2012; 35(11):660-70. PMC: 3493469. DOI: 10.1016/j.tins.2012.08.001. View

Shiba Y, Gomibuchi T, Seto T, Wada Y, Ichimura H, Tanaka Y . Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts. Nature. 2016; 538(7625):388-391. DOI: 10.1038/nature19815. View

Ichise H, Nagano S, Maeda T, Miyazaki M, Miyazaki Y, Kojima H . NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs. Stem Cell Reports. 2017; 9(3):853-867. PMC: 5599245. DOI: 10.1016/j.stemcr.2017.07.020. View

Umekage M, Sato Y, Takasu N . Overview: an iPS cell stock at CiRA. Inflamm Regen. 2019; 39:17. PMC: 6717959. DOI: 10.1186/s41232-019-0106-0. View

Piao J, Zabierowski S, Dubose B, Hill E, Navare M, Claros N . Preclinical Efficacy and Safety of a Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell. 2021; 28(2):217-229.e7. PMC: 7903922. DOI: 10.1016/j.stem.2021.01.004. View

10.

Schweitzer J, Song B, Herrington T, Park T, Lee N, Ko S . Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. N Engl J Med. 2020; 382(20):1926-1932. PMC: 7288982. DOI: 10.1056/NEJMoa1915872. View

11.

Louveau A, Smirnov I, Keyes T, Eccles J, Rouhani S, Peske J . Structural and functional features of central nervous system lymphatic vessels. Nature. 2015; 523(7560):337-41. PMC: 4506234. DOI: 10.1038/nature14432. View

12.

Snyder T, Khush K, Valantine H, Quake S . Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci U S A. 2011; 108(15):6229-34. PMC: 3076856. DOI: 10.1073/pnas.1013924108. View

13.

Morizane A, Kikuchi T, Hayashi T, Mizuma H, Takara S, Doi H . MHC matching improves engraftment of iPSC-derived neurons in non-human primates. Nat Commun. 2017; 8(1):385. PMC: 5577234. DOI: 10.1038/s41467-017-00926-5. View

14.

Okita K, Matsumura Y, Sato Y, Okada A, Morizane A, Okamoto S . A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011; 8(5):409-12. DOI: 10.1038/nmeth.1591. View

15.

Badin R, Bugi A, Williams S, Vadori M, Michael M, Jan C . MHC matching fails to prevent long-term rejection of iPSC-derived neurons in non-human primates. Nat Commun. 2019; 10(1):4357. PMC: 6761126. DOI: 10.1038/s41467-019-12324-0. View

16.

Freed C, Greene P, Breeze R, Tsai W, DuMouchel W, Kao R . Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001; 344(10):710-9. DOI: 10.1056/NEJM200103083441002. View

17.

Dengu F . Next-generation sequencing methods to detect donor-derived cell-free DNA after transplantation. Transplant Rev (Orlando). 2020; 34(3):100542. DOI: 10.1016/j.trre.2020.100542. View

18.

Piccini P, Pavese N, Hagell P, Reimer J, Bjorklund A, Oertel W . Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain. 2005; 128(Pt 12):2977-86. DOI: 10.1093/brain/awh649. View

19.

Jain P, Chaney A, Carlson M, Jackson I, Rao A, James M . Neuroinflammation PET Imaging: Current Opinion and Future Directions. J Nucl Med. 2020; 61(8):1107-1112. PMC: 7413228. DOI: 10.2967/jnumed.119.229443. View

20.

Takahashi J . iPS cell-based therapy for Parkinson's disease: A Kyoto trial. Regen Ther. 2021; 13:18-22. PMC: 7794047. DOI: 10.1016/j.reth.2020.06.002. View